Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson’s disease  by DeMarshall, Cassandra A. et al.
P
d
C
N
U
R
a
b
c
d
e
a
A
R
R
1
A
A
K
P
A
D
P
B
1
P
s
I
M
h
0
0Immunology Letters 168 (2015) 80–88
Contents lists available at ScienceDirect
Immunology  Letters
j our na l ho me page: www.elsev ier .com/ locate / immlet
otential  utility  of  autoantibodies  as  blood-based  biomarkers  for  early
etection  and  diagnosis  of  Parkinson’s  disease
assandra  A.  DeMarshall a,b,c,  Min  Hana,b,c,  Eric  P.  Nagelea,e, Abhirup  Sarkara,b,c,
imish  K.  Acharyaa,c, George  Godseyb,c, Eric  L.  Goldwasera,b,c, Mary  Kosciuka,c,
mashanger  Thayasivamd, Benjamin  Belinkae,
obert  G.  Nagelea,c,e,∗,  On  behalf  of:  The  Parkinson’s  Study  Group  Investigators
Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA
Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA
Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA
Department of Mathematics, Rowan University, Glassboro, NJ, USA
Durin Technologies, Inc., New Brunswick, NJ, USA
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 11 June 2015
eceived in revised form
4 September 2015
ccepted 14 September 2015
vailable online 16 September 2015
eywords:
arkinson’s disease
utoantibodies
iagnosis
rotein microarrays
iomarkers
a  b  s  t  r  a  c  t
Introduction:  There  is  a great  need  to identify  readily  accessible,  blood-based  biomarkers  for  Parkinson’s
disease  (PD)  that are  useful  for  accurate  early  detection  and  diagnosis.  This  advancement  would  allow
early patient  treatment  and  enrollment  into  clinical  trials,  both  of which  would  greatly  facilitate  the
development  of new  therapies  for  PD.
Methods:  Sera  from  a total  of  398 subjects,  including  103 early-stage  PD  subjects  derived  from  the
Deprenyl  and Tocopherol  Antioxidative  Therapy  of Parkinsonism  (DATATOP)  study,  were  screened  with
human  protein  microarrays  containing  9,486  potential  antigen  targets  to identify  autoantibodies  poten-
tially  useful  as  biomarkers  for PD. A panel  of  selected  autoantibodies  with  a higher  prevalence  in
early-stage  PD  was  identiﬁed  and tested  using  Random  Forest  for  its ability  to  distinguish  early-stage  PD
subjects  from  controls  and  from  individuals  with  other  neurodegenerative  and  non-neurodegenerative
diseases.
Results:  Results  demonstrate  that  a  panel  of  selected,  blood-borne  autoantibody  biomarkers  can  distin-
guish  early-stage  PD  subjects  (90%  conﬁdence  in  diagnosis)  from  age-  and  sex-matched  controls  with
an  overall  accuracy  of 87.9%,  a  sensitivity  of  94.1%  and  speciﬁcity  of  85.5%.  These  biomarkers  were  also
capable  of differentiating  patients  with  early-stage  PD  from  those  with  more  advanced  (mild-moderate)
PD  with  an  overall  accuracy  of  97.5%,  and could  distinguish  subjects  with  early-stage  PD  from  those  with
other  neurological  (e.g.,  Alzheimer’s  disease  and  multiple  sclerosis)  and  non-neurological  (e.g.,  breast
cancer)  diseases.
Conclusion:  These  results  demonstrate,  for the ﬁrst  time,  that  a panel  of selected  autoantibodies  may
prove to be  useful  as  effective  blood-based  biomarkers  for the  diagnosis  of  early-stage  PD.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. IntroductionCurrently, there are no simple and reliable diagnostic tests for
arkinson’s disease (PD). It remains essentially a clinical diagno-
is, subject to variations in patient presentation and physician
∗ Corresponding author at: Department of Geriatrics and Gerontology, New Jersey
nstitute for Successful Aging, Rowan University School of Osteopathic Medicine, 2
edical Center Drive, Stratford, NJ 08084, USA.
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165-2478/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
awareness. Even in subjects with an apparently positive response
to dopaminergic medication, a clinical diagnosis of PD can have
relatively poor accuracy [1]. Results are worse for early-stage
PD subjects [2]. Neuroimaging approaches such as dopamine
transporter (DaT) scanning have some utility, but are expensive,
invasive, and lack speciﬁcity. Thus, there remains a great need for an
accurate, inexpensive, and noninvasive test that can detect early-
stage PD.
Recently, many laboratories have been investigating new diag-
nostic strategies that are focusing on protein, lipid and microRNA
biomarkers that are detectable in the blood in response to the
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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resence of disease [3–5]. For example, in the ﬁeld of Alzheimer’s
isease, a number of studies have identiﬁed panels of these
lood-based biomarkers that may  be useful for detection of this dis-
ase which are currently under development [3,6,7]. Comparable
evelopments for biomarkers of PD have lagged behind. Detection
f biomarkers in the cerebrospinal ﬂuid (CSF) or blood presumably
ssociated with PD pathogenesis, such as alpha-synuclein or DJ-1,
ave thus far failed to yield consistent results [8–12]. Our previous
tudies have shown that autoantibodies should be added to the list
f blood proteins that have potential as useful biomarkers of disease
13,14]. These autoantibodies are abundant and ubiquitous in the
lood, and their levels are inﬂuenced by a variety of factors includ-
ng age, gender, and the presence of disease [15–17]. In previous
tudies, we have identiﬁed autoantibodies in human sera that can
erve as biomarkers to diagnose mild-moderate stages of PD with
n overall accuracy of 97.1%, with comparable results also obtained
or mild-moderate Alzheimer’s disease (AD) [13,14].
Our earlier success at identifying speciﬁc autoantibody
iomarkers capable of detecting mild-moderate PD prompted the
resent study, the goal of which was to determine if a separate
anel of autoantibodies can also be used for accurate detection and
iagnosis of early-stage PD. To test this possibility, sera from a total
f 398 subjects, including 103 early-stage PD subjects from the
eprenyl and Tocopherol Antioxidative Therapy of Parkinsonism
DATATOP) study with 90% conﬁdence in diagnosis, were analyzed
ith human protein microarrays to identify useful autoantibody
iomarkers for early-stage PD. These biomarkers were evaluated
or their ability to distinguish early-stage PD subjects from controls,
rom individuals with mild-moderate PD and from individuals with
ther neurodegenerative and non-neurodegenerative diseases.
. Methods
.1. Ethics statement
Approval for use of serum samples in this study was obtained
rom the Rowan-Stratford Institutional Review Board.
.2. Participants
103 early-stage PD samples from subjects participating in the
ATATOP study were obtained in coordination with the Michael J.
ox Foundation and Parkinson Study Group. These came from sub-
ects participating in the DATATOP study, which was a clinical trial
nvestigating the potential beneﬁcial effects of two  anti-oxidative
herapies, deprenyl and tocopherol, with the goal of delaying the
ime at which patients progress to disability requiring levodopa
reatment [18]. Diagnosis of PD was made with follow-up at 90%
onﬁdence by DATATOP clinical investigators, with each patient
etermined to have a Hoehn and Yahr scale score ranging from 1
o no greater than 2 [18]. Twenty-nine mild-moderate PD and 50
ild-moderate Alzheimer’s disease serum samples were obtained
rom Analytical Biological Systems, Inc. (Wilmington, DE). Thirty
tages 0-2 breast cancer (BC) serum samples were obtained from
sterand, Inc. (Detroit, MI), and 30 multiple sclerosis (MS) patient
erum samples were obtained from BioServe Biotechnologies Ltd.
Beltsville, MD). Healthy age- and sex-matched control sera were
btained from several sources: 40 from Analytical Biological Sys-
ems, Inc., 65 from BioServe Biotechnologies Ltd., 28 from Asterand
nc., and 23 from The New Jersey Institute for Successful Aging at
owan University (Stratford, NJ). All samples were handled using
tandard procedures and stored at −80 ◦C until use. Demographic
haracteristics of the study population are displayed in Table 1.y Letters 168 (2015) 80–88 81
2.3. Human protein microarrays
To identify autoantibodies in human sera, we  used Invitrogen’s
ProtoArray v5.0Human Protein Microarrays (Cat. No. PAH0525020,
Invitrogen, Carlsbad, CA, USA), each containing 9,486 unique human
protein antigens (www.invitrogen.com/protoarray). Arrays were
probed with serum diluted 1:500 and scanned to detect the Alex-
aFluor 647 reporter (Cat.No. A-21445, Invitrogen)  according to the
manufacturer’s instructions using a GenePix 4000B Fluorescence
Scanner (Molecular Devices, Sunnyvale, CA, USA).
2.4. Microarray data analysis
Fluorescence data was  acquired by aligning the Genepix Array
List (GAL) onto the microarray using Genepix Pro analysis software.
The resulting Genepix Results (GPR) ﬁles were imported into Invitro-
gen’s Prospector 5.2 for analysis and biomarker selection. The “group
characterization” and “two – group comparison” features in the
IRBP Toolbox within Prospector then enabled M-statistical analysis
of differential autoantibody expression between the two subjects
groups. Positive hits were determined by a Z-Factor greater than
0.4, and a minimum signal intensity of 1500 RFU, which allow for
stringent biomarker selection and minimizes the amount of false
positives. Autoantibodies were sorted into descending order by dif-
ference of prevalence between early-stage PD and control groups,
and the top 50 most differentially expressed autoantibodies were
chosen as our selected panel of diagnostic biomarkers. All raw
data has been deposited for public access in a MIAME compliant
database (GEO) under accession number GSE62283.
The predictive classiﬁcation accuracy of the selected biomark-
ers in the Training Set, Testing Set, and both sets combined was
tested with R’s Random Forest (RF)  (v 4.6-10), using default set-
tings [19–21]. Selected biomarkers were tested with the RF model
algorithm, and classiﬁcation accuracy is reported in a confusion
matrix. Receiver operating characteristic curves (ROCs), widely
used to evaluate the utility of a diagnostic test, were generated
using R(3.02) packages ROCR(v 1.0-5) and pROC(v 1.7.3) [6,22].
3. Results
3.1. Selection of a panel of autoantibody biomarkers for
early-stage PD diagnosis
Previously published data from our laboratory has highlighted
the potential utility of autoantibodies as blood-based biomarkers
for diagnosing mild-moderate PD [13]. Here, we used the same
strategy to search for biomarkers useful for early-stage PD detec-
tion (Fig. 1). Early-stage PD serum samples (n = 103) from patients
with a clinical diagnosis of PD at 90% conﬁdence and 111 age- and
sex- matched control samples (total n = 214) (Table 1) were ran-
domly separated into Training and Testing Sets. The Training Set
samples were used only for biomarker selection and contained
52 early-stage PD samples and 56 controls. The Testing Set sam-
ples, which were used to evaluate the performance of the selected
biomarkers, were not involved in the biomarker selection process
and included 51 early-stage PD and 55 control samples. Human
protein microarrays containing 9486 antigens were probed with
Training or Testing Set sera. Using Prospector analysis software,
2470 autoantibodies with a signiﬁcantly (p < .05) higher prevalence
in the early-stage PD group compared to controls were identiﬁed
in the Training Set as potential diagnostic biomarkers. From this
list, the top 50 most differentially expressed autoantibodies in the
early-stage PD subject group were chosen as a working diagnostic
panel of biomarkers (Supplementary Table 1).
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Table  1
Subject demographics. For each disease group the number of individuals (n), age, range of age, gender, and ethnicity are listed. For the early-stage PD subjects, the Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS) and Hoehn and Yahr scores are included as indices of PD severity.
Group n Age Sex Ethnicity UPDRS Hoehn & Yahr
(Years) (Range) (% Male) (% Caucasian)
Parkinson’s disease 132 65.1 ± 10.3 37–88 57 89 – –
-Early-stage 103 62.7 ± 9.3 37–79 58 98 38.1 ± 16.8 2.1 ± 0.6
-Mild-moderate 29 74.3 ± 9.0 53–88 55 55 – –
Controls 156 55.0 ± 15.6 19–87 56 76 – –
-Age-matched 111 63.1 ± 8.4 51–87 56 78 – –
-Non-age-matched 45 34.9 ± 10.2 19–50 49 71
Alzheimer’s disease 50 78.5 ± 8.8 61–97 42 88 – –
Multiple sclerosis 30 51.0 ± 9.2 36–67 33 97 – –
Breast cancer 30 46.9 ± 5.8 32–54 0 97 – –
Fig. 1. Biomarker selection and Training/Testing Set analysis strategy. The total sample pool (n = 214) was randomly split into two groups: a Training Set and Testing Set.
Prospector statistical analysis was performed on the Training Set to identify the top 50 most differentially expressed autoantibody classiﬁers in early-stage PD samples
compared to controls. The diagnostic accuracy of these selected biomarkers was tested by using Random Forest to predict sample classiﬁcation in the Training Set. This logic
was  then applied to the analysis of the Testing Set, and then both sets combined. The values represent an average of ﬁve runs for each of the three steps of the biomarker
discovery and validation process.
Table 2
a and b. Diagnostic results using panels of 50 and four early-stage PD biomarkers, respectively. The performance of the top 50 and top four early-stage PD autoantibody
biomarkers was  assessed using RF.  Using the original logic, RF successfully distinguished the early-stage PD samples of the Testing Set (n = 51) from age- and sex-matched
controls,  age-matched plus younger controls, mild-moderate PD, mild-moderate AD, multiple sclerosis and breast cancer with high overall accuracies. PPV, positive predictive
value;  NPV, negative predictive value.
(a)
Early-stage PD (n = 51) vs.
Age-matched controls Mild-moderate PD Mild-moderate AD Multiple sclerosis Breast cancer
n  55 29 50 30 30
Sensitivity% 94.1 96.1 94.1 94.1 96.1
Speciﬁcity% 85.5 100.0 100.0 100.0 100.0
PPV%  85.7 100.0 100.0 100.0 100.0
NPV% 94.0 93.6 94.3 90.9 93.8
Overall accuracy% 87.9 97.5 97.0 96.3 97.5
Overall error% 12.1 2.5 3.0 3.7 2.5
(b)
Early-stage PD (n = 51) vs.
Age-matched controls Mild-moderate PD Mild-moderate AD Multiple sclerosis Breast cancer
n  55 29 50 30 30
Sensitivity% 84.3 90.2 92.2 84.3 90.2
Speciﬁcity% 83.6 100.0 100.0 100.0 96.7
3
a
SPPV%  82.7 100.0 
NPV% 85.2 85.3 
Overall accuracy% 84.0 93.7 
Overall error% 16.0 6.3 .2. Veriﬁcation of biomarkers via training and testing set
nalyses
The top 50 autoantibody biomarkers chosen from the Training
et serum samples as the early-stage PD diagnostic panel were100.0 100.0 97.9
92.6 79.0 85.3
96.0 90.1 92.6
4.0 9.9 7.4then re-veriﬁed as signiﬁcant predictors by Random Forest (RF).
Upon evaluation of Training Set samples (n = 108; 52 early-stage
PD, 56 controls) utilizing these 50 biomarkers, early-stage PD sub-
jects were distinguished from age- and sex-matched controls with
C.A. DeMarshall et al. / Immunology Letters 168 (2015) 80–88 83
Fig. 2. (a and b) ROC assessment of autoantibody biomarkers for detection of early-stage PD in Testing Set subjects and PD progression. a. Comparison of early-stage PD
(n  = 51) vs. age-matched controls (n = 55) using a panel of 50 (red line) or 4 (blue line) PD biomarkers shows that these biomarker panels can be used to detect early-stage PD
with  relatively high overall accuracy. The dashed line represents the line of no discrimination. b. Comparison of early-stage Testing Set PD subjects (n = 51) vs. mild-moderate
PD  subjects (n = 29) using a panel of 50 (red line) or 4 (blue line) early-stage PD biomarkers shows that these biomarkers can be used to accurately distinguish these two
different stages of PD progression. The ROC AUC, sensitivity, and speciﬁcity values for the 50 and 4 biomarkers used for this purpose are shown in Table 3.
Table 3
ROC curve analysis of diagnostic results using the early-stage PD Testing Set. ROC curve analysis was  used to assess the diagnostic utility of the panels of 50 and four selected
biomarkers for distinguishing early-stage PD subjects from age-matched controls from the subject groups listed. Areas under the curve (AUC) at 95% conﬁdence are listed
along  with values for sensitivity and speciﬁcity derived from the ROC curve output data.
50 Markers 4 Markers
Early-stage PD (n = 51) vs. AUC (95% CI) Sensitivity (95% CI) Speciﬁcity (95% CI) AUC (95% CI) Sensitivity (95% CI) Speciﬁcity (95% CI)
Age-matched controls n = 55) 0.92(0.87, 0.98) 0.94(0.88, 1.0) 0.87(0.78, 0.94) 0.91(0.86, 0.96) 0.84(0.74, 0.94) 0.87(0.76, 0.90)
Mild-moderate PD (n = 29) 0.97(0.94, 1.0) 0.96(0.90, 1.0) 1.0(1.0, 1.0) 0.98(0.95, 1.0) 0.96(0.90, 1.0) 1.0(1.0, 1.0)
Mild-moderate AD (n = 50) 0.99(0.97, 1.0) 0.93(0.89, 0.98) 0.96(0.90, 1.0) 0.98(0.94, 1.0) 0.96(0.9, 1.0) 0.98(0.94, 1.0)
Multiple sclerosis (n = 30) 0.97(0.94, 1.0) 0.96(0.90, 1.0) 1.0(1.0, 1.0) 0.97(0.94, 1.0) 0.96(0.90, 1.0) 1.0(1.0, 1.0)
Breast  cancer (n = 30) 0.98(0.95, 1.0) 0.96(0.90, 1.0) 0.97(0.9, 1.0) 0.98(0.95, 1.0) 0.96(0.97, 1.0) 0.97(0.90, 1.0)
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n average of 91.8% prediction accuracy. We  then used the same
0 biomarkers and Training Set logic for unbiased classiﬁcation of
arly-stage PD in Testing Set samples which were not involved in
iomarker selection. RF correctly classiﬁed early-stage PD in Test-
ng Set subjects (n =n106; 51 early-stage PD, 55 controls) with an
verage accuracy of 87.9% (Table 2a). Diagnostic sensitivity, speci-
city, and positive and negative predictive values for the panel
f 50 early-stage PD biomarkers using only Testing Set subjects
re shown in Table 2a. The diagnostic utility of this biomarker
anel for distinguishing early-stage PD Testing Set subjects from
ge-matched controls was also evaluated using Receiver Operat-
ng Characteristic (ROC) curve analysis [23] (Fig. 2a, red line). The
OC area under the curve (AUC) for this comparison was 0.92, indi-
ating excellent classiﬁcation accuracy (Table 3). Finally, combining
raining and Testing Set samples (total n = 214), RF successfully dis-
inguished early-stage PD from controls with an average overall
ccuracy of 88.5%.
.2. Minimum number of autoantibodies required for accurate
iagnosis of early-stage PD
To determine the minimum number of autoantibody biomark-
rs required to achieve the best diagnostic accuracy, the 50 selected
arly-stage PD biomarkers were ﬁrst sorted according to decreas-
ng relative importance, and then successively removed from the
ottom of the list until the overall diagnostic accuracy began to
ecline signiﬁcantly. Using this approach, we determined that a
anel of four biomarkers (the top four biomarkers listed in Supple-
entary Table 1) was the minimum number required to maintain
n effective diagnostic accuracy (ROC AUC = 0.91; sensitivity = 0.84;
peciﬁcity = 0.87) for distinguishing early-stage PD subjects from
ge-matched controls (Fig. 2a, blue line; Table 3).
.3. Speciﬁcity of the selected biomarker panels for early-stage PD
The speciﬁcity of the selected autoantibody biomarker panels
or early-stage PD was tested to determine if they could distinguish
arly-stage PD from other neurological and non-neurological dis-
ases. To eliminate the possibility that the selected PD biomarker
anels were simply detecting non-speciﬁc CNS degeneration, the
ame 51 early-stage PD sera from Testing Set subjects were com-
ared to sera from 50 patients with Alzheimer’s disease (AD) and
0 sera from patients with multiple sclerosis (MS). Using the panel
f 50 biomarkers, early-stage PD sera were readily distinguished
rom AD sera with an overall accuracy of 97.0% (sensitivity = 94.1%;
peciﬁcity = 100.0%) (Table 2a). ROC curve analysis yielded an AUC
f 0.99 and a sensitivity and speciﬁcity of 0.93 and 0.96, respec-
ively (Table 3). Using the panel of four biomarkers yielded an
verall accuracy of 96.0% (ROC AUC = 0.98; sensitivity = 0.96; speci-
city = 0.98) (Tables 2 b and 3). Both biomarker panels were capable
f readily distinguishing early-stage PD from MS  subjects with com-
arable overall accuracy (Tables 2 a,b and 3).
We then sought to determine the speciﬁcity of the early-stage
D diagnostic biomarkers in the context of non-neurological dis-
ase, in this case breast cancer. Results showed that 30 breast
ancer (BC) serum samples were successfully differentiated from
he 51 early-stage, Testing Set PD samples with an overall accuracy
f 97.5% (sensitivity = 96.1%; speciﬁcity = 100.0%; ROC AUC = 0.98)
or the panel of 50 biomarkers (Tables 2 a and 3). ROC analysis
sing the panel of four biomarkers yielded an overall accuracy of
2.6%, an AUC of 0.98, a sensitivity of 0.96, and speciﬁcity of 0.97
Tables 2 b and 3). These results demonstrate that the panels of 50
nd four PD autoantibody biomarkers were comparably accurate
n distinguishing early-stage PD subjects from patients with other
eurological and non-neurological diseases.y Letters 168 (2015) 80–88
3.4. Use of PD biomarkers to distinguish early- from later-stages
of PD progression
We  next asked whether the panels of 50 and four early-
stage PD biomarkers could distinguish early-stage PD from later
stages with more advanced pathology. To address this, the 51
early-stage, Testing Set PD serum samples were compared to 29
mild/moderate-stage PD samples using RF.  Early-stage PD samples
were correctly classiﬁed with an overall accuracy of 97.5% (sensi-
tivity = 96.1%; speciﬁcity = 100.0%) (Table 2a) and ROC AUC of 0.97
(Fig. 2b, red line; Table 3) using the panel of 50 biomarkers. Com-
parable results were obtained with the panel of four early-stage PD
biomarkers (Fig. 2b, blue line; Table 3). These ﬁndings emphasize
the high level of speciﬁcity of these biomarker panels for the diag-
nosis of early-stage PD, and also suggest the potential utility of this
approach for identifying discrete stages of PD disease progression
as illustrated in Fig. 3. Lastly, comparison of the top 50 biomark-
ers for early-stage and mild-moderate PD revealed an overlap of
21 biomarkers (Supplementary Table 2), conﬁrming the expected
presence of common biomarkers between these disease stages.
3.5. Effects of addition of younger controls on biomarker selection
and diagnostic accuracy
There is a growing realization that most CNS diseases are pre-
ceded by long prodromal phases of ongoing, gradually escalating
pathology for many years prior to the emergence of detectable
symptoms [24–27]. This reality makes it very difﬁcult for sam-
ples derived from our aging population to be both age-matched
and unequivocally pathology-free. To investigate the impact of this
potential limitation, we  tested the effects of including younger,
non-age-matched controls on the initial selection of early-stage
PD autoantibody biomarkers. To accomplish this, 52 early-stage PD
samples were compared to a control group composed of 56 age-
matched and 45 additional younger, non-age-matched controls. As
described above, the top 50 early-stage PD autoantibody biomark-
ers were selected in Prospector on the basis of prevalence difference
between the two groups. The utility of these 50 new biomarkers for
distinguishing early-stage PD (n = 103) subjects from age-matched
controls (n = 111) was  then veriﬁed using RF, yielding an overall
diagnostic accuracy of 88.8%, a sensitivity of 93.2% and speciﬁcity
of 84.7%. When all early-stage PD samples (n = 103) were com-
pared to all age-matched and non-age-matched controls (n = 156;
111 age-matched, 45 non-age-matched) these biomarkers yielded
an overall diagnostic accuracy of 90.4%, a sensitivity of 94.2%, and
a speciﬁcity of 87.8%. These results were comparable to those
obtained using the original 50 biomarkers described above. This
is not surprising considering that, among the 50 new early-PD
biomarkers, 32 were found to overlap with the previous set of 50
biomarkers that were derived from inclusion of only age- and sex-
matched controls, and the identities of the four top biomarkers
remained unchanged (Fig. 4).
4. Discussion
Our previous studies have shown that autoantibodies are abun-
dant and ubiquitous in human sera, numbering in the many
thousands, and that individual autoantibody proﬁles are strongly
inﬂuenced by age, gender and the presence of disease [13,14,16].
Further, differential autoantibody expression proﬁles can be used
to detect and diagnose mild-moderate PD and AD using a small
volume of serum or plasma and human protein microarrays as a
diagnostic platform [13,14]. In the present study, we sought to
extend the capacity and potential clinical utility of this approach by
attempting to identify autoantibody biomarkers that can diagnose
C.A. DeMarshall et al. / Immunology Letters 168 (2015) 80–88 85
Fig. 3. Utility and hypothetical origin of autoantibodies useful for PD diagnosis and staging. It is well-known that by the time symptoms emerge at early-stage PD, the majority
of  neurons in the substantia nigra (red dot in brain) have already died, and it is assumed that their debris (red particles) is liberated into the surrounding brain tissue. Some
of  this debris makes its way  into the blood, activates the immune system, and elicits the production of corresponding autoantibodies. In early-stage PD, the site of pathology
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nd  spreading of PD pathology during later disease stages (e.g., mild-moderate PD) 
nd  yellow) autoantibody proﬁles. For each disease stage, autoantibodies exhibitin
arly-stage PD as well as distinguish early- from mild-moderate-
tage PD.
To accomplish this, we obtained sera from subjects enrolled in
he DATATOP study through the Michael J. Fox Foundation and
arkinson’s Study Group. These subjects were diagnosed initially
nd later conﬁrmed at subsequent patient visits with early-stage
D with at least 90% conﬁdence based on functional, motor, cogni-
ive, and psychiatric assessments [18]. The DATATOP clinical trial
as aimed at testing the potential beneﬁcial effects of two antiox-
dative therapies, deprenyl and tocopherol, on the progression of
D. These agents were found to have no discernable beneﬁcial
ffects on PD progression [18]. Autoantibody biomarker proﬁles
or DATATOP subjects with early-stage PD were obtained and com-
ared with age- and sex-matched controls as well as with sera from
D patients with more advanced (mild-moderate) disease. We  ini-
ially identiﬁed a panel containing the top 50 PD autoantibody
iomarkers that was able to distinguish early-stage PD subjects
rom age- and sex-matched controls. Concerning the top 50 cho-
en biomarkers, it is important to point out that the majority are
xpressed in both early-stage PD and controls; however, those in
arly-stage PD subjects demonstrate signiﬁcant fold increases in
xpression compared to corresponding controls. We  then veriﬁed
heir signiﬁcance and predictive value using an independent Test-
ng Set containing subjects that were not involved in the biomarker
iscovery process. Results showed an accuracy for early-stage PD
etection of 87.9%, a sensitivity of 94.1% and a speciﬁcity of 85.5%.
OC curve assessment of the utility of the diagnostic yielded an AUC
f 0.92 with 50 biomarkers and 0.91 with four biomarkers. Since it
s generally considered desirable for a diagnostic test to have a sen-
itivity and speciﬁcity greater than 85%, the two biomarker panels
or early-stage PD detection described here exceed these criteria fores is likewise limited (red autoantibodies). It is reasonable to expect that escalation
o more abundant and complex (red and yellow) debris and disease-associated (red
ost dramatic and consistent changes are selected as the useful biomarkers.
the speciﬁc population studied [28]. Among the 50 PD autoantibody
biomarkers identiﬁed, the top four represent the minimum num-
ber required for accurate detection and diagnosis of early-stage PD.
Moreover, both panels of biomarkers are speciﬁc in differentiat-
ing early-stage PD from other neurological and non-neurological
diseases, such as AD, MS,  and breast cancer.
The panels of 50 and four autoantibody biomarkers described
here have also allowed us to distinguish early-stage PD from mild-
moderate PD with overall accuracies of 97.5% (sensitivity = 96.1%,
speciﬁcity = 100.0%) for the 50 biomarkers and 93.7% (sensitiv-
ity = 90.2%, speciﬁcity = 100.0%) for the four biomarkers. ROC curve
analysis yielded an AUC of 0.97 for the 50 biomarkers and 0.98
for the four biomarkers for this application. A diagnostic test capa-
ble of distinguishing different stages of PD severity may  make it
possible to follow a patient’s disease course, rate of progression,
and response to therapies. This would be useful for physicians and
their patients as well as for enabling early enrollment of PD subjects
into clinical trials and monitoring of therapeutic efﬁcacy through
a patient’s response to new treatments. Of course, for the latter, a
positive patient response would be a delay of disease progression
to the next stage or an improvement from the current disease state
as evidenced by curtailed symptoms. Any slowing or stopping of
disease progression resulting from diminished pathology would be
expected to be accompanied by a corresponding reduction in levels
of disease-associated autoantibodies (Fig. 3).
It is widely recognized that the pathogenesis of a number of
neurodegenerative diseases is initiated many years prior to the
emergence of clinically useful symptoms. For effective and accu-
rate identiﬁcation of biomarkers directly linked to pathology, the
selection of truly pathology-free controls is just as important
as the selection of subjects with conﬁrmed pathology. However,
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Fig. 4. Effect of younger controls on biomarker selection and diagnostic importance. Gini plot demonstrating the relative importance of 30 of the top 50 biomarkers to the
RF  classiﬁcation decision when comparing early-stage PD to age-matched controls plus younger healthy controls. Biomarkers are sorted according to decreasing relative
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ight  side of the plot. Note that the identities of the top 4 biomarkers remain uncha
ithout the aid of telltale symptoms during prodromal phases of
isease, it is difﬁcult to ensure that age-matched controls being
sed for biomarker discovery are truly pathology-free. This may  be
specially problematic for diseases like AD where, due to a com-
ination of high prevalence and a long prodromal period, a large
raction of individuals are likely to have presymptomatic pathol-
gy. Admittedly, this is much less of a problem with PD because
f the relatively low prevalence of PD within the elderly pop-
lation. Nevertheless, the difﬁculty of obtaining pathology-free
ontrols would be expected to hinder biomarker discovery efforts
s well as the possibility of achieving pre-symptomatic disease
etection.
To investigate strategies that may  aid in compensating for
his inherent study limitation, we tested the effects of purposely
dding a subset of younger controls to the control subject pool on
iagnostic accuracy. We  predicted that adding truly pathology-freesiﬁcation decision indicated by the extent of deﬂection of the indicator point to the
controls (albeit younger and non-age-matched) to the control sub-
ject group should improve diagnostic outcome by emphasizing the
non-pathology features of autoantibody proﬁles common to both
groups. For a disease with a relatively low prevalence, such as PD,
we speculate that the number of compensatory younger controls
added should be relatively low—in this case perhaps no more than
5% of the total control population. However, for diseases with a
much higher prevalence and longer prodromal period, such as AD,
the percentage of compensatory younger controls added should be
higher.
Surprisingly, in most blood-based biomarker discovery studies
completed thus far for various diseases, the biomarkers showing
the greatest utility generally do not include those expected based
on their presumed role in the pathology [21,29,30]. In the present
study, biomarker selection was  dependent solely on prevalence
differences between early-stage PD and controls, so as not to be
unolog
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nﬂuenced by previously reported biomarker candidates. In fact,
any of the 50 PD autoantibody biomarkers chosen as the top
ifferentiators for early-stage PD follow this trend, with no obvi-
us or expected PD-related standouts such as lpha-synuclein.
nstead, the most useful PD biomarkers selected here include some
ith a well-known neuronal connection, while others represent
 wide variety of cellular functions and diverse molecular path-
ays. Among the former, microtubule-afﬁnity regulating kinase
 (MARK1) is a mediator of microtubule stability and is thought
o be involved in neuronal migration and differentiation through
hosphorylation of tau and other microtubule-associated proteins
31]. Hyperphosphorylation of tau, leading to the production of
euroﬁbrillary tangles, has been identiﬁed as a pathological hall-
ark of neurodegenerative diseases such as AD and, more recently,
n PD [32,33]. Interestingly, two paralogs of MARK1, brain spe-
iﬁc kinase-1 (BRSK1), and microtubule-afﬁnity regulating kinase
 (MARK4) were also identiﬁed as important differential biomark-
rs in our diagnostic panel, suggesting a correlation to a largely
nexplored pathway that could be involved in the early stages of
D pathology and progression. A 2011 study by Pickens et al. has
emonstrated increased levels of the proinﬂammatory cytokine C-
 motif chemokine 19 (CCL19) in synovial ﬂuid from patients with
ither rheumatoid arthritis or psoriatic arthritis relative to con-
rols [34]. Increased levels of another proinﬂammatory cytokine,
nterleukin 20 (IL20), have also been documented in patients
ith both rheumatoid arthritis and psoriasis [35,36]. Several other
iomarkers identiﬁed here have been implicated in the regulation
f the cell cycle, transcription and translation, as well as GTPases,
NA, and other small molecules. In addition to the biomarkers
escribed above, a subset of the 50 identiﬁed PD biomarkers
as yet to be characterized and their functions currently remain
nknown.
In conclusion, we describe panels of PD autoantibody biomark-
rs that can differentiate early-stage PD subjects from age-matched
ontrols, within the population studied, with a diagnostic accu-
acy of 87.9% using a minute volume of serum and human protein
icroarrays as a diagnostic platform. Because the subjects used
ere were diagnosed with early-stage PD with 90% conﬁdence, it is
ncouraging that our overall diagnostic accuracy comes close to
his 90% value. Thus, we anticipate an increase in overall accu-
acy when testing PD subjects with initial diagnostic conﬁdence
alues approaching 100%, and such studies are currently being
lanned. Furthermore, we show that these panels can distinguish
arly-stage PD subjects from those with more advanced disease
s well as differentiate them from other neurodegenerative and
on-neurodegenerative diseases with high accuracy, again, within
he study population. Further veriﬁcation studies will be necessary
o conﬁrm comparable diagnostic accuracies in the broader pop-
lation. The development of a sensitive and speciﬁc, blood-based
iagnostic test for early-stage PD could have a profound clinical
mpact on the early treatment of PD patients who currently rely on
ymptoms alone for diagnosis. The use of these PD autoantibody
iomarkers could fundamentally change the way PD progression is
onitored in trials of potential therapies.
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